Welcome to your Weekly Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
TriNetX Unveils Conversational AI Interface and Enhanced API Capabilities
TriNetX, a global leader in real-world data solutions, shared results demonstrating how its TriNetX LIVE platform is reshaping the way pharmaceutical companies plan and conduct clinical trials. By combining extensive real-world data with artificial intelligence, the platform has reduced costly protocol changes and improved the speed and accuracy of site identification, providing measurable benefits for researchers and sponsors.
Toothio Tackles Dental Workforce Crisis with Industry’s First AI Recruiting Agent
Toothio, a leading digital staffing platform for dental practices, has unveiled Mel, the first AI-powered recruiting agent specifically designed for healthcare. Mel allows dental offices and dental service organizations to instantly source, engage, and hire credentialed professionals nationwide, streamlining the hiring process in real time. Unlike traditional recruiting methods that rely on job boards or manual outreach, Mel automatically identifies qualified candidates, develops personalized engagement plans, and communicates through text, email, and phone. The system responds intelligently to questions and preferences, creating a fully automated pipeline that reduces both time-to-hire and cost-per-hire while enabling practices to focus on patient care.
RXNT Named 2026 Gartner Digital Markets Leader in Healthcare
RXNT, a Maryland-based provider of ambulatory healthcare technology solutions, has been named a 2026 Gartner Digital Markets Leader. The recognition includes five Shortlist awards and five FrontRunner awards, highlighting the company’s excellence in medical billing, practice management, electronic medical records, mental health, and physical therapy software. Verified users praised RXNT’s software for simplifying office workflows, consolidating payments and patient reminders in one platform, and making day-to-day operations more efficient.
NeuroQure Launches First Functional Biophysical Autism Test
NeuroQure, a leader in neurological diagnostics, has introduced ASD Insight, the first test designed to identify autism risk at birth. This innovative approach marks a significant step toward understanding autism as a biologically measurable condition rather than one diagnosed solely through observation. ASD Insight gives clinicians and families the ability to detect risk early, enabling targeted interventions during critical stages of neurodevelopment and improving long-term outcomes for children.
BIOMAKERS Secures $8 Million to Expand Precision Oncology Platform
BIOMAKERS, a precision medicine and oncology intelligence company headquartered in San Francisco, announced the closing of an additional $8 million. The financing marks a key inflection point as the company transitions from building a differentiated global diagnostics and data infrastructure to scaling an AI-native platform – while continuing to expand its comprehensive molecular testing reach across Latin America – designed to accelerate drug and diagnostic development, improve clinical trial execution, and enable precision oncology at global scale.
Inspira Health Appoints Warren Moore as President and COO
Inspira Health has announced the appointment of Warren E. Moore, FACHE, as President and Chief Operating Officer of the health system. In this expanded role, Moore will oversee operations across all Inspira hospitals, health centers, and outpatient facilities while continuing to strengthen strategic partnerships that improve access to care and advance clinical excellence across South Jersey. Moore previously served as Executive Vice President and Chief Operating Officer, where he played a key role in supporting Inspira’s mission to provide safe, compassionate care and improve the health and well-being of local communities.
AbbVie Reports Phase 3 Epcoritamab Results in DLBCL
AbbVie shared topline findings from the Phase 3 EPCORE DLBCL-1 trial, which evaluated epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, against investigator-chosen chemoimmunotherapy in adult patients with relapsed or refractory diffuse large B-cell lymphoma. The study showed that epcoritamab improved progression-free survival with a hazard ratio of 0.74 and a 95 percent confidence interval ranging from 0.60 to 0.92. Patients treated with epcoritamab also experienced higher complete response rates, longer duration of response, and extended time to next treatment. The trial did not show a statistically significant improvement in overall survival with a hazard ratio of 0.96 and a 95 percent confidence interval of 0.77 to 1.20.
Novartis Ianalumab Gains FDA Breakthrough Status for Sjögren’s Disease
Novartis announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ianalumab for Sjögren’s disease, the second most prevalent rheumatic autoimmune disease. Ianalumab is a fully human monoclonal antibody with a novel dual mechanism of action that depletes B-cells and inhibits their activation and survival via BAFF-R blockade. Novartis plans to submit ianalumab for regulatory approval globally starting in early 2026. If approved, ianalumab would become the first targeted treatment for patients with Sjögren’s disease.
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
Telix Pharmaceuticals Limited announces that the first patient in the United States (U.S.) has been dosed in BiPASS, a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET imaging agents, Illuccix and Gozellix in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies.
SOLUM and Alltrack Medical Partner on Smart Healthcare Management
SOLUM, a global leader in retail solutions, has partnered with Alltrack Medical, a Dutch company at the forefront of digital healthcare innovation, to introduce advanced connected solutions that enhance efficiency and sustainability in healthcare operations. The collaboration combines SOLUM’s proven technology with Alltrack Medical’s expertise in healthcare logistics to create a more connected, streamlined, and data-driven ecosystem for hospitals, clinics, and other care facilities.
H.I.G. Realty and Barts NHS Launch First Life Sciences Project
H.I.G. Capital, a leading global alternative investment firm managing $74 billion in assets, has announced a strategic partnership with Barts Health NHS Trust to develop the first applied healthcare innovation building within the newly established Barts Life Sciences Cluster on Cavell Street in Whitechapel, London. The project brings together one of the largest NHS Trusts in the UK, a global investment firm, and a specialist science and technology developer to create new models of collaboration between clinicians, researchers, and industry partners. Spanning 170,000 square feet, the Cavell Street development is positioned as a landmark within the Cluster, signaling a new phase of health innovation in East London focused on merging clinical expertise with commercial capability.
EQT Life Sciences co-leads €51M Series B for Exciva Alz Phase 2
EQT Life Sciences has announced that its LSP Dementia Fund has joined as a co-lead investor in a EUR 51 million Series B financing round for Exciva, a clinical-stage biopharmaceutical company focused on developing new treatments for behavioral symptoms linked to Alzheimer’s disease. The funding marks a significant step forward for the company as it prepares to advance its lead therapy into mid-stage clinical development, addressing an area of high unmet medical need within neurodegenerative care.
CareXM Introduces AI Voice Agent to Improve Patient Access and Preserve Clinician Capacity
CareXM has announced the launch of an AI Voice Agent within its non-clinical answering platform, designed to help healthcare providers manage growing call volumes without increasing operational pressure. The new system replaces traditional IVR menus with natural conversational dialogue that engages patients immediately, captures multiple requests in a single call, sequences follow-ups for care teams, and escalates urgent clinical needs to providers in real time.
To share your insights, please write to us at sudipto@intentamplify.com
